K.J. Harrison & Partners Inc Sells 2,208 Shares of Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

K.J. Harrison & Partners Inc lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,825 shares of the company’s stock after selling 2,208 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Johnson & Johnson were worth $1,368,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JNJ. Thoroughbred Financial Services LLC boosted its stake in shares of Johnson & Johnson by 14,147.0% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Nordea Investment Management AB boosted its stake in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after acquiring an additional 1,079,751 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Johnson & Johnson by 152.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock worth $122,372,000 after acquiring an additional 654,085 shares during the last quarter. Royal London Asset Management Ltd. boosted its stake in Johnson & Johnson by 53.2% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock worth $199,471,000 after acquiring an additional 648,775 shares during the last quarter. Finally, Jensen Investment Management Inc. boosted its stake in Johnson & Johnson by 23.6% during the 2nd quarter. Jensen Investment Management Inc. now owns 2,903,660 shares of the company’s stock worth $404,422,000 after acquiring an additional 554,783 shares during the last quarter. 67.23% of the stock is currently owned by hedge funds and other institutional investors.

Shares of JNJ stock opened at $128.07 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The company has a market capitalization of $337.10 billion, a P/E ratio of 15.66, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. The company’s 50 day moving average price is $131.66 and its two-hundred day moving average price is $136.44. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the company posted $2.10 EPS. Analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

In related news, Director Marillyn A. Hewson bought 3,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.

Several research analysts recently weighed in on JNJ shares. Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Barclays started coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 price objective on the stock. Finally, Bank of America reissued a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What is the market perform rating?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Patron  Price Hits $0.0002 on Major Exchanges
Patron Price Hits $0.0002 on Major Exchanges
Profile Utility Token Market Capitalization Achieves $85,220.00
Profile Utility Token Market Capitalization Achieves $85,220.00
AICHAIN  Trading Down 11.3% Over Last 7 Days
AICHAIN Trading Down 11.3% Over Last 7 Days
TEMCO  Price Tops $0.0009 on Major Exchanges
TEMCO Price Tops $0.0009 on Major Exchanges
New Residential Investment  Lowered to “Sell” at Zacks Investment Research
New Residential Investment Lowered to “Sell” at Zacks Investment Research
Sanofi SA  Given Consensus Rating of “Buy” by Brokerages
Sanofi SA Given Consensus Rating of “Buy” by Brokerages


© 2006-2019 Ticker Report